The 2028 Patent Cliff Forces Pharma into Creative Biosimilar Settlement Terms
With over $200 billion in branded biologic revenues losing exclusivity by 2030, originator drugmakers are navigating secondary patent litigation under aggressive FTC antitrust scrutiny.
The biopharmaceutical industry is approaching the steepest patent cliff in modern commercial history. Between 2026 and 2030, foundational biologic blockbusters representing over $200 billion in annual global branded revenues, including pembrolizumab (Keytruda), apixaban (Eliquis), nivolumab (Opdivo), and ustekinumab (Stelara), will lose primary composition-of-matter patent protection across the United States and Europe.
To defend commercial franchises, originator pharmaceutical companies constructed extensive patent thickets comprising dozens of secondary formulation, dosage regimen, and manufacturing process patents. However, heightened antitrust enforcement from the Federal Trade Commission and European competition regulators is fundamentally altering how originators settle patent disputes with biosimilar challengers.
Legal filings in federal district courts reveal that originator companies are negotiating structured, tiered market-entry agreements with biosimilar developers. These settlements grant licensed commercial launch windows years before secondary patent expiry while carefully avoiding reverse-payment structures or suspect value transfers that trigger federal antitrust prosecution.
The Subcutaneous Life-Cycle Defense
Alongside patent litigation settlements, commercial sponsors are executing rapid lifecycle transitions to proprietary subcutaneous bio-formulations. By co-formulating intravenous monoclonal antibodies with recombinant human hyaluronidase (such as Halozyme's ENHANZE technology), drugmakers convert multi-hour hospital infusions into rapid five-minute subcutaneous injections.
Securing separate patent protection on novel subcutaneous delivery architectures allows originators to transition 50% to 70% of their commercial patient volume onto protected subcutaneous products before intravenous biosimilars enter the market. Because hospital pharmacy formularies and oncology clinics favor the operational efficiency of rapid subcutaneous administration, intravenous biosimilars capture smaller market share upon launch.
However, healthcare payers and pharmacy benefit managers are pushing back against automatic formulation switching, implementing strict step-therapy protocols requiring patients to fail lower-cost biosimilar intravenous options before approving branded subcutaneous formulations.
Accelerating Late-Stage Pipeline Acquisitions
The looming loss of revenue exclusivity has unleashed an unprecedented wave of targeted biopharmaceutical acquisitions. Major pharmaceutical primes with strong corporate balance sheets are aggressively acquiring clinical-stage biotech assets possessing projected commercial launch windows between 2026 and 2028 to replace impending revenue declines.
For mid-sized clinical biotechs, the patent cliff creates a highly competitive seller's market, driving premium acquisition multiples for de-risked Phase 2 and Phase 3 programs across oncology, immunology, and metabolic disease.